NewsBenzingaLucid Diagnostics : BPA ajusté T3 à (0,06 $), conforme, ventes à 1,203 M$ en dessous de l’estimation de 1,635 M$ Lucid Diagnostics : BPA ajusté T3 à (0,06 $), conforme, ventes à 1,203 M$ en dessous de l’estimation de 1,635 M$ Benzinga 2026.11.12 13:05 (GMT+0) Open on Benzinga Other news Leerink Partners Initiates Coverage On Erasca with Outperform Rating, Announces Price Target of $35 What's Going on With AST SpaceMobile Stock on Monday? Reported November 16, U.S. CMS Issues Proposed Rule To Target Fraud Across Medicare, Medicaid/CHIP, And The Marketplace; Sees Possible Savings Of $90B Over Next 10 Years Stock of the Day: Is Pepsi About to Break Out? Intel Extends Slide as Nvidia Trims Stake 25%, Shareholder Suit Adds Pressure HC Wainwright & Co. Maintains Buy on Soluna Holdings, Lowers Price Target to $3
Reported November 16, U.S. CMS Issues Proposed Rule To Target Fraud Across Medicare, Medicaid/CHIP, And The Marketplace; Sees Possible Savings Of $90B Over Next 10 Years